{"entity":{"id":"opp-ceacam5-imaging-colorectal","kind":"opportunity","name":"CEACAM5 imaging for occult colorectal recurrence","aka":["CEA PET","CEACAM5 PET"],"tldr":"After bowel cancer surgery, a rising blood marker often signals that the cancer is back, but scans frequently cannot say where. The one scan ever approved for that exact problem was withdrawn from the market in 2005 and nothing has replaced it.","summary":"The clinical scenario is specific and common: a treated colorectal cancer patient's serum CEA rises during surveillance while CT, MRI and colonoscopy are normal or equivocal. Salvage surgery or ablation can still cure oligometastatic recurrence, but only if the disease can be localised. Arcitumomab (CEA-Scan), a technetium-99m anti-CEA antibody fragment approved for precisely this indication, was withdrawn from both the US and EU markets in 2005; clinicians now fall back on FDG PET/CT off-label, which in one referred series found recurrence in 56 of 88 such patients.\n\nMeanwhile the therapeutic side of CEACAM5 has grown: antibody-drug conjugates, T-cell engagers and CAR-T programmes target it, and the field has learned that CEA-directed therapy selection is not the same question as CEA-directed localisation. The most advanced CEACAM5-directed imaging agent in humans is not a PET tracer at all but SGM-101, a near-infrared fluorescent anti-CEA antibody for intraoperative use, now in a randomised phase 3 trial (NCT03659448, about 300 patients). For PET, the most advanced is the CEA-targeted nanobody 68Ga-HNI01 at first-in-human scale, nine patients.\n\nThe competitive picture changed independently of imaging. Tumour-informed ctDNA now detects recurrence a median of 5.9 months before radiological recurrence in GALAXY/CIRCULATE-Japan, and ctDNA-guided adjuvant therapy was non-inferior to standard management in DYNAMIC while halving chemotherapy use. ctDNA says whether and roughly when; it does not say where. That distinction is the whole of the case for a CEACAM5 tracer, and it is a stronger case now than when CEA-Scan was withdrawn, because more patients are being flagged as molecularly positive with nothing to localise.","asOf":"2026-09-23","links":[{"label":"FDG PET/CT for occult colorectal recurrence with raised CEA","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC5153343/"},{"label":"NCT03659448: SGM-101 phase 3 in colorectal cancer","url":"https://clinicaltrials.gov/study/NCT03659448"},{"label":"GALAXY: ctDNA lead time over radiological recurrence, Nature Medicine 2024","url":"https://www.nature.com/articles/s41591-024-03254-6"},{"label":"DYNAMIC: ctDNA-guided adjuvant therapy in stage II colon cancer","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC9701133/"},{"label":"CT nodal staging accuracy meta-analysis","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13394594/"}],"tags":["unmet need first","colorectal","recurrence","ctDNA"],"related":["ga-68","f-18","tc-99m"],"indications":["colorectal-cancer"],"sections":[],"technologies":["immuno-pet","pet-ct","fdg-pet"],"targets":["ceacam5"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"lens":"unmet-need-first","unmetNeed":"When serum CEA or a ctDNA assay says a treated colorectal cancer has recurred but CT, MRI and colonoscopy cannot find it, no approved molecular imaging agent localises the disease well enough to plan salvage surgery.","useCase":"A colorectal multidisciplinary team would scan the patient whose CEA or ctDNA has turned positive with negative conventional imaging, to find and localise resectable recurrence, and would also use it for peritoneal and nodal mapping before an attempted curative resection. The output that matters is a lesion a surgeon can go to.","hypothesis":"A CEACAM5-specific PET agent will localise recurrent colorectal cancer in patients with rising CEA or detectable ctDNA and negative conventional imaging at a higher rate and with fewer false positives than FDG PET/CT, because it reports a lineage-specific antigen rather than glucose metabolism shared with inflammation.","rationale":"The target is expressed in the large majority of colorectal adenocarcinomas and the approach has regulatory precedent: an anti-CEA imaging agent was once approved for this indication. FDG PET/CT already works well enough in this setting to be used off-label, which establishes both that the clinical question is real and that the bar for a specific agent is a meaningful improvement over FDG rather than over nothing. The population being referred for localisation is growing because ctDNA surveillance flags molecular recurrence months before imaging, and antibody fragments and nanobodies now give same-day kinetics that arcitumomab's generation could not.","test":"A prospective study in patients with rising CEA or positive tumour-informed ctDNA and negative conventional imaging, comparing a CEACAM5 PET agent head to head with FDG PET/CT in the same patients, with histopathology or 12-month follow-up as the truth standard, and reporting the proportion of patients in whom the scan identified a resectable lesion that changed management.","maturity":"early-clinical","verdict":"standalone-and-companion","mostAdvanced":"SGM-101, a fluorescent anti-CEA antibody for intraoperative use from Surgimab, in a randomised phase 3 trial of about 300 patients; for PET specifically, the nanobody 68Ga-HNI01 at nine patients.","dueDiligence":[{"domain":"target-biology","state":"strong","why":"CEACAM5 is a long-established colorectal lineage antigen; serum CEA is in every surveillance guideline, and an anti-CEA imaging agent was once approved for occult recurrence, so in-vivo targeting is proven in principle.","source":"Arcitumomab regulatory history","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC5153343/"},{"domain":"clinical-evidence","state":"thin","why":"No CEACAM5 PET agent has gone beyond first-in-human; the nanobody 68Ga-HNI01 has nine patients. The only phase 3 CEA-directed imaging agent is a fluorescence agent for use in the operating theatre, not a tracer.","source":"NCT03659448 and first-in-human nanobody report","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC7892528/"},{"domain":"diagnostic-performance","state":"moderate","why":"The incumbent, FDG PET/CT, detected recurrence in 56 of 88 patients referred with raised CEA and negative conventional imaging, so any new agent must beat a working off-label comparator rather than fill a void.","source":"FDG PET/CT in occult colorectal recurrence","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC5153343/","weighted":true},{"domain":"safety-dosimetry","state":"none","why":"No published dosimetry for a current-generation CEACAM5 PET agent at a scale worth quoting; the withdrawn technetium-99m fragment is not a guide to a gallium-68 or fluorine-18 construct."},{"domain":"regulatory-path","state":"moderate","why":"A direct precedent exists in the same indication, which is unusual: arcitumomab was approved for occult colorectal recurrence before being withdrawn in 2005, so the endpoint and claim structure have been accepted once.","source":"Arcitumomab history","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC5153343/","weighted":true}],"flags":[{"category":"technical","flag":"amber","why":"Bowel and liver background is the hard part of abdominal imaging, and the antigen is shed into serum, which can blunt tumour uptake; a fragment or nanobody format is probably required."},{"category":"unmet-need","flag":"green","why":"A defined, guideline-recognised scenario with no approved agent since 2005, and a population growing because ctDNA surveillance flags recurrence earlier than imaging can localise it."},{"category":"ip","flag":"amber","why":"CEA binders are a crowded, decades-old space with many antibodies and fragments in therapeutic programmes; novelty would have to come from format and chelation rather than the binding site."},{"category":"commercial","flag":"amber","why":"The localisation use stands alone, but the scan is a one-off per recurrence episode in a surveillance population, so volume depends on how widely ctDNA surveillance is adopted."},{"category":"isotope","flag":"green","why":"Gallium-68 or fluorine-18 on a fragment gives same-day imaging; no supply constraint."},{"category":"competition","flag":"green","why":"No company has a disclosed late-stage CEACAM5 PET programme; the phase 3 activity is in fluorescence-guided surgery, which is complementary rather than competing."}],"competition":[{"name":"Surgimab","what":"SGM-101, a fluorescent anti-CEA antibody for intraoperative delineation of colorectal and peritoneal disease, in a randomised phase 3 trial of about 300 patients.","stage":"phase 3","url":"https://clinicaltrials.gov/study/NCT03659448"},{"name":"Academic nanobody programmes","what":"68Ga-HNI01, a CEA-targeted nanobody, first-in-human at nine patients.","stage":"phase 1","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC7892528/"},{"name":"ctDNA surveillance (Natera and others)","what":"Tumour-informed ctDNA detects recurrence a median of 5.91 months before radiological recurrence in GALAXY, creating the patients who need localising.","stage":"in clinical use","url":"https://www.nature.com/articles/s41591-024-03254-6"}],"differentiation":"Serum CEA misses up to 70% of recurrences and ctDNA says whether and when but not where: a positive ctDNA result with negative imaging is a management dilemma, not an answer. A CEACAM5 tracer competes with FDG PET/CT, not with the blood tests, and its case is specificity in an abdomen full of physiological FDG uptake.","metrics":[{"label":"Recurrences detected by FDG PET/CT in patients with raised CEA and negative conventional imaging","value":"56 of 88","source":"Occult recurrence series","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC5153343/"},{"label":"Lead time of tumour-informed ctDNA over radiological recurrence","value":"5.91 months median","source":"GALAXY, Nature Medicine 2024","url":"https://www.nature.com/articles/s41591-024-03254-6"},{"label":"Pooled sensitivity and specificity of CT for nodal staging in colorectal cancer","value":"69% and 66%","source":"Meta-analysis of 29 studies, 5,634 people","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13394594/"},{"label":"Colorectal recurrences that occur without CEA elevation","value":"up to 70%","source":"Permanente Journal review","url":"https://www.thepermanentejournal.org/doi/10.7812/TPP/18-022"}],"risks":["FDG PET/CT is already good enough in this scenario for many teams, so the margin a specific agent must beat is not zero.","Shed circulating CEA can compete with tumour binding and blunt contrast, which is a formulation and format problem rather than a target problem.","If ctDNA-guided management moves toward treating molecular recurrence systemically without localising it, the surgical rationale for a localising scan narrows."],"watch":["The randomised SGM-101 phase 3 readout, which will show whether CEA-directed imaging changes surgical outcomes at all, in any modality.","Any CEACAM5 PET agent entering a trial with rising CEA or ctDNA positivity as the enrolment criterion rather than known measurable disease.","Guideline language on what to do with a positive ctDNA and a negative scan, which is where the demand for this agent will be written down."]},"route":"/opportunities/opp-ceacam5-imaging-colorectal/","neighbours":{"isotope":[{"id":"f-18","kind":"isotope","name":"Fluorine-18","route":"/isotopes/f-18/"},{"id":"ga-68","kind":"isotope","name":"Gallium-68","route":"/isotopes/ga-68/"},{"id":"tc-99m","kind":"isotope","name":"Technetium-99m","route":"/isotopes/tc-99m/"}],"indication":[{"id":"colorectal-cancer","kind":"indication","name":"Colorectal cancer","route":"/indications/colorectal-cancer/"}],"technology":[{"id":"fdg-pet","kind":"technology","name":"FDG PET","route":"/technologies/fdg-pet/"},{"id":"immuno-pet","kind":"technology","name":"Immuno-PET","route":"/technologies/immuno-pet/"},{"id":"pet-ct","kind":"technology","name":"PET/CT","route":"/technologies/pet-ct/"}],"target":[{"id":"ceacam5","kind":"target","name":"CEACAM5","route":"/targets/ceacam5/"}]}}